JP2008533191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008533191A5 JP2008533191A5 JP2008502453A JP2008502453A JP2008533191A5 JP 2008533191 A5 JP2008533191 A5 JP 2008533191A5 JP 2008502453 A JP2008502453 A JP 2008502453A JP 2008502453 A JP2008502453 A JP 2008502453A JP 2008533191 A5 JP2008533191 A5 JP 2008533191A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- alkyl
- alaninyl
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 229910019142 PO4 Inorganic materials 0.000 claims 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 7
- 239000010452 phosphate Substances 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- UENGBOCGGKLVJJ-UHFFFAOYSA-N 2-chloro-1-(2,4-difluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CCl)C(F)=C1 UENGBOCGGKLVJJ-UHFFFAOYSA-N 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 claims 2
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 claims 2
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0505781.5 | 2005-03-21 | ||
| GBGB0505781.5A GB0505781D0 (en) | 2005-03-21 | 2005-03-21 | Chemical compounds |
| PCT/GB2006/000932 WO2006100439A1 (en) | 2005-03-21 | 2006-03-16 | Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013097919A Division JP5863702B2 (ja) | 2005-03-21 | 2013-05-07 | 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008533191A JP2008533191A (ja) | 2008-08-21 |
| JP2008533191A5 true JP2008533191A5 (OSRAM) | 2009-04-30 |
| JP5345381B2 JP5345381B2 (ja) | 2013-11-20 |
Family
ID=34531603
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502453A Expired - Fee Related JP5345381B2 (ja) | 2005-03-21 | 2006-03-16 | 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体 |
| JP2013097919A Expired - Fee Related JP5863702B2 (ja) | 2005-03-21 | 2013-05-07 | 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013097919A Expired - Fee Related JP5863702B2 (ja) | 2005-03-21 | 2013-05-07 | 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8263575B2 (OSRAM) |
| EP (1) | EP1866324B1 (OSRAM) |
| JP (2) | JP5345381B2 (OSRAM) |
| CN (2) | CN101175763A (OSRAM) |
| AT (1) | ATE471334T1 (OSRAM) |
| AU (1) | AU2006226182C1 (OSRAM) |
| BR (1) | BRPI0609704B8 (OSRAM) |
| CA (1) | CA2602324C (OSRAM) |
| CY (1) | CY1111538T1 (OSRAM) |
| DE (1) | DE602006014949D1 (OSRAM) |
| DK (1) | DK1866324T3 (OSRAM) |
| ES (1) | ES2348741T3 (OSRAM) |
| GB (1) | GB0505781D0 (OSRAM) |
| IL (1) | IL186104A (OSRAM) |
| MX (1) | MX2007011666A (OSRAM) |
| PL (1) | PL1866324T3 (OSRAM) |
| PT (1) | PT1866324E (OSRAM) |
| SI (1) | SI1866324T1 (OSRAM) |
| WO (1) | WO2006100439A1 (OSRAM) |
| ZA (1) | ZA200709011B (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0623493D0 (en) * | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| AU2012216500B2 (en) * | 2006-11-24 | 2013-06-20 | Katholieke Universiteit Leuven | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
| CA2749394A1 (en) | 2009-01-09 | 2010-07-15 | University College Of Cardiff Consultants Limited | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections |
| WO2011123668A2 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Stereoselective synthesis of phosphorus containing actives |
| GB201016855D0 (en) * | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| US9351989B2 (en) | 2010-12-29 | 2016-05-31 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
| CN103403014B (zh) * | 2011-01-03 | 2016-07-06 | 河南美泰宝生物制药有限公司 | O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途 |
| HRP20160346T1 (hr) * | 2011-03-01 | 2016-05-06 | Nucana Biomed Limited | Fosforoamidatni derivati 5-fluoro-2'-deoksiuridina za upotrebu u tretmanu raka |
| US9085599B2 (en) | 2011-03-16 | 2015-07-21 | Enanta Pharmaceuticals, Inc. | 2′allene-substituted nucleoside derivatives |
| ES2627195T3 (es) | 2012-11-16 | 2017-07-27 | University College Cardiff Consultants Limited | Mezcla de RP/SP gemcitabina-[fenil-(bencloxi-l-alaninil)]-fosfato |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| KR20160099090A (ko) * | 2013-11-27 | 2016-08-19 | 아이데닉스 파마슈티칼스 엘엘씨 | 간암의 치료를 위한 뉴클레오티드 |
| CA2947939A1 (en) * | 2014-05-28 | 2015-12-03 | Idenix Pharmaceuticals Llc | Nucleoside derivatives for the treatment of cancer |
| CN106459127A (zh) * | 2014-05-28 | 2017-02-22 | 艾登尼克斯药业有限公司 | 用于治疗癌症的核苷衍生物 |
| KR102548806B1 (ko) | 2014-11-28 | 2023-06-27 | 뉴카나 피엘씨 | 항암제로서 새로운 2' 및/또는 5' 아미노산 에스테르 포스포르아미데이트 3'-디옥시아데노신 유도체 |
| WO2016144918A1 (en) | 2015-03-06 | 2016-09-15 | Atea Pharmaceuticals, Inc. | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
| CN108431016A (zh) * | 2015-11-16 | 2018-08-21 | 艾可瑞恩治疗公司 | 核酸前体药物 |
| GB201522764D0 (en) * | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609602D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201609601D0 (en) * | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| US10711029B2 (en) | 2016-07-14 | 2020-07-14 | Atea Pharmaceuticals, Inc. | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| SG11201901457TA (en) | 2016-09-07 | 2019-03-28 | Atea Pharmaceuticals Inc | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
| US11202792B2 (en) * | 2016-10-12 | 2021-12-21 | Georgetown University | CD99 inhibitors and their uses |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
| JP2020164521A (ja) * | 2019-03-29 | 2020-10-08 | 国立大学法人 長崎大学 | 抗ウィルス薬 |
| GB201904544D0 (en) | 2019-04-01 | 2019-05-15 | NuCana plc | Anticancer compounds |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
| CN113549076B (zh) * | 2021-07-23 | 2022-12-06 | 中国药科大学 | 一种多取代嘌呤类化合物及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR880000094B1 (ko) | 1984-12-07 | 1988-02-23 | 보령제약 주식회사 | 뉴클레오시드 유도체의 제조방법 |
| CA2004695C (en) | 1988-12-12 | 1999-08-10 | Rosanne Bonjouklian | Phospholipid nucleosides |
| DE4418690A1 (de) | 1994-05-28 | 1996-01-11 | Boehringer Mannheim Gmbh | Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel |
| GB9505025D0 (en) * | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| JP4313847B2 (ja) * | 1995-04-21 | 2009-08-12 | ユニヴァーシティ オブ サウス フロリダ | 免疫賦活性イノシン一リン酸の５’−ヌクレオチダーゼ抵抗性誘導体およびその使用 |
| JP3761958B2 (ja) * | 1996-03-12 | 2006-03-29 | 彰 松田 | ３′−カルバモイルアルキルヌクレオシド誘導体 |
| ES2172303T3 (es) * | 1998-01-23 | 2002-09-16 | Newbiotics Inc | Agentes terapeuticos obtenidos por catalisis enzimatica. |
| GB9821058D0 (en) * | 1998-09-28 | 1998-11-18 | Univ Cardiff | Chemical compound |
| JP4768909B2 (ja) * | 2000-09-29 | 2011-09-07 | 扶桑薬品工業株式会社 | トポイソメラーゼ阻害剤 |
| US20030073618A1 (en) | 2001-02-08 | 2003-04-17 | Kozhemyakin Leonid A. | Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof |
| DE10108851A1 (de) * | 2001-02-23 | 2002-09-12 | Resprotect Gmbh | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten |
| BR0210594A (pt) | 2001-06-22 | 2005-11-01 | Pharmasset Ltd | (beta)-d ou (beta)-l-3-halonucleosìdeo |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| GB0401088D0 (en) | 2004-01-19 | 2004-02-18 | Univ Cardiff | Phosphoramidate derivatives |
| AU2005267421B2 (en) * | 2004-06-24 | 2010-06-03 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| CN101287472B (zh) * | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
-
2005
- 2005-03-21 GB GBGB0505781.5A patent/GB0505781D0/en not_active Ceased
-
2006
- 2006-03-16 PL PL06710096T patent/PL1866324T3/pl unknown
- 2006-03-16 DE DE602006014949T patent/DE602006014949D1/de active Active
- 2006-03-16 WO PCT/GB2006/000932 patent/WO2006100439A1/en not_active Ceased
- 2006-03-16 CN CNA200680016708XA patent/CN101175763A/zh active Pending
- 2006-03-16 JP JP2008502453A patent/JP5345381B2/ja not_active Expired - Fee Related
- 2006-03-16 AT AT06710096T patent/ATE471334T1/de active
- 2006-03-16 CN CN201410186829.5A patent/CN103936807A/zh active Pending
- 2006-03-16 AU AU2006226182A patent/AU2006226182C1/en not_active Ceased
- 2006-03-16 DK DK06710096.6T patent/DK1866324T3/da active
- 2006-03-16 ES ES06710096T patent/ES2348741T3/es active Active
- 2006-03-16 SI SI200630762T patent/SI1866324T1/sl unknown
- 2006-03-16 EP EP06710096A patent/EP1866324B1/en active Active
- 2006-03-16 BR BRPI0609704A patent/BRPI0609704B8/pt not_active IP Right Cessation
- 2006-03-16 PT PT06710096T patent/PT1866324E/pt unknown
- 2006-03-16 CA CA2602324A patent/CA2602324C/en active Active
- 2006-03-16 MX MX2007011666A patent/MX2007011666A/es active IP Right Grant
- 2006-03-16 ZA ZA200709011A patent/ZA200709011B/xx unknown
- 2006-03-16 US US11/886,931 patent/US8263575B2/en not_active Expired - Fee Related
-
2007
- 2007-09-20 IL IL186104A patent/IL186104A/en active IP Right Grant
-
2010
- 2010-09-10 CY CY20101100826T patent/CY1111538T1/el unknown
-
2013
- 2013-05-07 JP JP2013097919A patent/JP5863702B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008533191A5 (OSRAM) | ||
| JP2013537203A5 (OSRAM) | ||
| JP2005523922A5 (OSRAM) | ||
| JP2008505157A5 (OSRAM) | ||
| JP2019512478A5 (OSRAM) | ||
| JP2010530881A5 (OSRAM) | ||
| JP2007511504A5 (OSRAM) | ||
| JP2008528447A5 (OSRAM) | ||
| JP2004516314A5 (OSRAM) | ||
| CA2565660A1 (en) | Ortho substituted aryl or heteroaryl amide compounds | |
| JP2009535307A5 (OSRAM) | ||
| JP2008510828A5 (OSRAM) | ||
| JP2009502743A5 (OSRAM) | ||
| JP2009504763A5 (OSRAM) | ||
| JP2011509309A5 (OSRAM) | ||
| JP2006514012A5 (OSRAM) | ||
| JP2008510770A5 (OSRAM) | ||
| CA2545427A1 (en) | Selective kinase inhibitors | |
| JP2011526917A5 (OSRAM) | ||
| JP2014503574A5 (OSRAM) | ||
| JP2005539088A5 (OSRAM) | ||
| JP2002516817A5 (OSRAM) | ||
| JP2007501809A5 (OSRAM) | ||
| JP2018530582A5 (OSRAM) | ||
| JP2003306481A5 (OSRAM) |